Peggie Pelosi - Director | eXp World Holdings (EXPI) Executive Profile & Compensation

About Peggie Pelosi

Peggie Pelosi, 69, has over 20 years in sales and network development and 15 years as a corporate social responsibility and sustainability practitioner. She joined EXPI’s board in 2023 and currently serves as Chair of the Nominating & Corporate Governance Committee, Chair of the Sustainability Committee, and a member of the Audit Committee. She holds a graduate diploma in Corporate Social Responsibility & Sustainability (University of Toronto), NACD Directorship Certification (NACD.CD), and ESG Competent Boards Director Certification (GCB.D) .

Past Roles

Organization	Role	Tenure	Committees/Impact
USANA Health Sciences	Executive Director of Sales (Canada)	1999–2000	Network development leadership
USANA Health Sciences	Vice President, Network Development	2000–2004	Expanded direct-selling operations
Orenda Social Purpose	Founding Partner & Strategic Advisor	Sep 2005–present	CSR strategy advisory
Innovators Alliance	Executive Director	2015–Mar 2023	CEO network focused on sustainable growth

External Roles

Organization	Role	Tenure	Committees
USANA Health Sciences, Inc. (NYSE:USNA)	Independent Director	Since 2018	Audit; Compensation; Governance, Risk & Nominating; Chair, Sustainability

Notable interlock: EXPI’s General Counsel, James Bramble, previously served as CLO/GC/Corporate Secretary at USANA until 2018 (potential information-flow link; not a direct conflict) .

Board Governance

Item	Detail
Independence	Board determined all members except Glenn Sanford (CEO/Chair) and Monica Weakley (Agent Director) are independent; Pelosi is independent .
Committee roles	Chair, Nominating & Corporate Governance; Chair, Sustainability; Member, Audit .
2024 meetings	Board: 4; Audit: 5; Nominating & Gov: 6; Compensation: 6; Sustainability: 4 .
Attendance	All incumbent directors attended ≥75% of Board and committee meetings; Pelosi met attendance threshold .
Governance evolution	Company ceased “controlled company” status July 31, 2023; Compensation Committee transitioned to fully independent membership by May 21, 2024 .

Fixed Compensation

Component	Amount (2024)	Notes
Annual independent director cash retainer	$200,000	Paid monthly; standardized for independent directors .
Nominating & Corporate Governance Chair fee	$25,000	Paid monthly .
Sustainability Chair fee	$25,000	Paid monthly .
Total cash compensation (Pelosi)	$250,000	Sum of retainer + chair fees .

Performance Compensation

Award Type	Grant Date	Size	Vesting	Performance Metrics
Stock options (initial independent director grant)	Jan 26, 2023	33,371 options	Monthly over 3 years, continued service	None disclosed for directors; time-based vesting only .

Equity Policy Reference	Detail
Independent director equity policy	Initial stock option award with grant date accounting fair value approximately $300,000; monthly vest over 3 years; annual options of ~$100,000 begin in 4th year; monthly vest over 3 years .

Anti-hedging/pledging: Company prohibits directors from hedging, short sales, derivatives, and pledging of Company securities (alignment safeguard) .
Clawback: Applies to incentive comp tied to financial reporting for current/former executive officers (directors not targeted) .

Other Directorships & Interlocks

Company	Sector Relationship to EXPI	Role/Committee	Interlock/Conflict Assessment
USANA Health Sciences, Inc.	Unrelated (nutrition/supplements)	Director; Audit; Compensation; Governance, Risk & Nominating; Chair Sustainability	Low conflict; note historic linkage via EXPI GC’s prior USANA employment .

Expertise & Qualifications

CSR/Sustainability leadership and governance: Orenda Social Purpose; ESG director certifications; Chair of EXPI Sustainability and USANA Sustainability .
Network development and commercial growth expertise from USANA operating roles .
Boardroom credentials: NACD Directorship Certification (NACD.CD); ESG Competent Boards Director Certification (GCB.D) .

Equity Ownership

Measure	Value
Beneficial ownership (as of Jan 31, 2025)	24,101 shares; less than 1% of class .
Composition of beneficial ownership	Includes stock options exercisable within 60 days: 24,101 .
Outstanding option awards (12/31/2024)	33,371 options outstanding .
Shares pledged/hedged	Prohibited by policy (hedging/pledging ban) .

Insider Trades

Item	Disclosure
Section 16(a) compliance (FY2024)	Company reports all reporting persons complied, except late Form 4s by Glenn Sanford and Penny Sanford; no delinquencies noted for Pelosi .

Governance Assessment

Board effectiveness: Pelosi strengthens independence and governance rigor through dual chair roles (Nominating & Governance; Sustainability) and Audit Committee membership; her committees met frequently in 2024 (Nominating: 6; Sustainability: 4; Audit: 5), indicating active oversight .
Alignment and incentives: Director pay is cash-heavy with time-based options; Pelosi’s 2024 cash ($250k) reflects leadership roles; equity vests over time without disclosed performance conditions—common for directors but lower “pay-for-performance” sensitivity versus executives .
Conflicts/related-party risk: Company reports no related-party transactions >$120,000 in 2024; anti-hedging/pledging policy in place; her USANA directorship is in an unrelated industry; historical tie via EXPI GC’s prior USANA role is a network link, not a current conflict .
Shareholder signals: EXPI improved governance post-controlled status and fully independent Compensation Committee by May 2024; say‑on‑pay support was ~95% in 2024, suggesting investor confidence in compensation oversight framework, though that pertains to executives more than directors .

RED FLAGS: None disclosed regarding related-party transactions, hedging/pledging, or attendance shortfalls; director equity is not performance-based, which is typical but provides limited performance linkage for directors .